MedPath

Clobetasol Propionate

Clobetasol Propionate Gel, 0.05% Clobetasol Propionate Cream USP, 0.05% Clobetasol Propionate Ointment USP, 0.05%

Approved
Approval ID

4a761afb-a48a-4a5a-8700-ad93601a260f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 7, 2025

Manufacturers
FDA

Sun Pharmaceutical Indutries, Inc.

DUNS: 146974886

FDA

Taro Pharmaceuticals U.S.A., Inc.

DUNS: 145186370

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Clobetasol Propionate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51672-1259
Application NumberANDA074248
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clobetasol Propionate
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 7, 2025
FDA Product Classification

INGREDIENTS (8)

propylene glycolInactive
Code: 6DC9Q167V3
Classification: IACT
Clobetasol PropionateActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB
sorbitan sesquioleateInactive
Code: 0W8RRI5W5A
Classification: IACT
petrolatumInactive
Code: 4T6H12BN9U
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
SORBITAN SESQUIOLEATEInactive
Code: 0W8RRI5W5A
Classification: IACT
PETROLATUMInactive
Code: 4T6H12BN9U
Classification: IACT
CLOBETASOL PROPIONATEActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB

Clobetasol Propionate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51672-1258
Application NumberANDA074249
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clobetasol Propionate
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 7, 2025
FDA Product Classification

INGREDIENTS (20)

chlorocresolInactive
Code: 36W53O7109
Classification: IACT
Clobetasol PropionateActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB
cetyl alcoholInactive
Code: 936JST6JCN
Classification: IACT
glyceryl monostearateInactive
Code: 230OU9XXE4
Classification: IACT
citric acid monohydrateInactive
Code: 2968PHW8QP
Classification: IACT
propylene glycolInactive
Code: 6DC9Q167V3
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT
sodium citrate, unspecified formInactive
Code: 1Q73Q2JULR
Classification: IACT
stearyl alcoholInactive
Code: 2KR89I4H1Y
Classification: IACT
white waxInactive
Code: 7G1J5DA97F
Classification: IACT
CETYL ALCOHOLInactive
Code: 936JST6JCN
Classification: IACT
CHLOROCRESOLInactive
Code: 36W53O7109
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
GLYCERYL MONOSTEARATEInactive
Code: 230OU9XXE4
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULR
Classification: IACT
STEARYL ALCOHOLInactive
Code: 2KR89I4H1Y
Classification: IACT
WHITE WAXInactive
Code: 7G1J5DA97F
Classification: IACT
CLOBETASOL PROPIONATEActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB

Clobetasol Propionate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51672-1294
Application NumberANDA075279
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clobetasol Propionate
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 7, 2025
FDA Product Classification

INGREDIENTS (10)

Carbomer Homopolymer Type B (Allyl Pentaerythritol Crosslinked)Inactive
Code: HHT01ZNK31
Classification: IACT
propylene glycolInactive
Code: 6DC9Q167V3
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT
Clobetasol PropionateActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB
CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)Inactive
Code: HHT01ZNK31
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
CLOBETASOL PROPIONATEActive
Quantity: 0.5 mg in 1 g
Code: 779619577M
Classification: ACTIB

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 8/7/2025

PRINCIPLE DISPLAY PANEL- 30G TUBE CARTON (SUN)

carton- sunNDC 51672-1294-2

Clobetasol Propionate Gel 0.05%

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 5/18/2023

ADVERSE REACTIONS

In a controlled clinical trial with clobetasol propionate gel, the only reported adverse reaction that was considered to be drug related was a report of burning sensation (1.8% of treated patients). In controlled clinical trials, the most frequent adverse reactions reported for clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin. In controlled clinical trials, the most frequent adverse events reported for clobetasol propionate ointment were burning sensation, irritation, and itching in 0.5% of treated patients. Less frequent adverse reactions were stinging, cracking, erythema, folliculitis, numbness of fingers, skin atrophy, and telangiectasia.

Cushing's syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 5/18/2023

Mfd. by: Sun Pharma Canada Inc., Brampton, Ontario, Canada L6T 1C1

Dist by:**Sun Pharmaceutical Industries,**Inc., Cranbury, NJ 08512

Revised: July 2025

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 5/18/2023

CLINICAL PHARMACOLOGY

Like other topical corticosteroids, clobetasol propionate has anti- inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours has not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Greater absorption was observed for the clobetasol propionate gel formulation as compared to the cream formulation in in vitro human skin penetration studies. Studies performed with clobetasol propionate gel, cream and ointment indicate that they are in the super-high range of potency as compared with other topical corticosteroids.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 5/18/2023

HOW SUPPLIED

Clobetasol Propionate Gel, 0.05% is supplied in tamper-evident tubes:15 g (NDC 51672-1294-1), 30 g (NDC 51672-1294-2), and 60 g (NDC 51672-1294-3).

Clobetasol Propionate Cream USP, 0.05% is supplied in tamper-evident tubes: 15 g (NDC 51672-1258-1), 30 g (NDC 51672-1258-2), 45 g (NDC 51672-1258-6), and 60 g (NDC 51672-1258-3).

Clobetasol Propionate Ointment USP, 0.05% is supplied in tamper-evident tubes: 15 g (NDC 51672-1259-1), 30 g (NDC 51672-1259-2), 45 g (NDC 51672-1259-6), and 60 g (NDC 51672-1259-3).

Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature].DO NOT REFRIGERATE

DESCRIPTION SECTION

LOINC: 34089-3Updated: 5/18/2023

DESCRIPTION

Clobetasol propionate gel, cream and ointment contain the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Clobetasol propionate is a white to cream-colored crystalline powder insoluble in water. Chemically, it is 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate, and it has the following structural formula:

Chemical Structure

Each gram of the 0.05% gel contains 0.5 mg clobetasol propionate in a base of carbomer 934P, propylene glycol, purified water, and sodium hydroxide.

Each gram of the 0.05% cream contains clobetasol propionate 0.5 mg in a cream base of cetyl alcohol, chlorocresol, citric acid, glyceryl monostearate, glyceryl stearate/polyethylene glycol 100 stearate, propylene glycol, purified water, sodium citrate, stearyl alcohol, and white wax.

Each gram of the 0.05% ointment contains clobetasol propionate 0.5 mg in a base of propylene glycol, sorbitan sesquioleate, and white petrolatum.

RECENT MAJOR CHANGES SECTION

LOINC: 43683-2Updated: 8/7/2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Clobetasol Propionate - FDA Drug Approval Details